{"id":"isv-403","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ISV-403 targets the Wnt signaling cascade, which plays a key role in pathological corneal neovascularization and fibrosis. By inhibiting this pathway, the drug aims to suppress abnormal blood vessel growth and reduce inflammatory responses in the cornea, thereby improving visual outcomes in corneal diseases.","oneSentence":"ISV-403 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:55.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Corneal neovascularization"},{"name":"Corneal scarring and fibrosis"}]},"trialDetails":[{"nctId":"NCT00348348","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":"Acute Bacterial Conjunctivitis","enrollment":1161},{"nctId":"NCT00347932","phase":"PHASE3","title":"A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":"Acute Bacterial Conjunctivitis","enrollment":957},{"nctId":"NCT00622908","phase":"PHASE2","title":"Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2004-12","conditions":"Bacterial Conjunctivitis","enrollment":270},{"nctId":"NCT01120418","phase":"PHASE1","title":"Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-05","conditions":"Healthy","enrollment":120},{"nctId":"NCT00407589","phase":"PHASE1","title":"Systemic Pharmacokinetics of BOL-303224-A","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-10","conditions":"Conjunctivitis, Bacterial","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["besifloxacin","Besivance","BOL-303224"],"phase":"phase_3","status":"active","brandName":"ISV-403","genericName":"ISV-403","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ISV-403 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation. Used for Corneal neovascularization, Corneal scarring and fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}